Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as "Anhui Poly"), a subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm."), has recently received the certificate of suitability for the European Pharmacopoeia (CEP) for the pharmaceutical excipient Betadex Sulfobutyl Ether Sodium issued by European Director for the Quality of Medicine&HealthCare (hereinafter referred to as "EDQM")
On June 19-21, 2024, the 22nd CPHI&PMEC China was grandly opened at the Shanghai New International Expo Center.Anhui Poly Pharm. Co., Ltd. has attracted widespread attention from the industry due to its technological service platform advantages in the fields of iodine/gadolinium contrast agents and synthetic biology, as well as CMO/CDMO services that comply with European and US cGMP standards. In addition, Poly Pharm. has rich experience in international R&D, registration, and sales.
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), recently received the approval notification of marketing application for chemical API Gadoterate Meglumine issued by NMPA (Notification No. 2024YS00506).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as "Anhui Poly"), a subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm."), has recently received the Notice of Approval about application for marketing of cyclophosphamide chemical raw material issued by the National Medicinal Product Administration (hereinafter referred to as "NMPA") (Notice number: 2024YS00429).
Anhui Poly Pharm. Co., Ltd., a wholly-owned subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm." or the "Company"), recently receives First Adequate Letter (FAL)for Gadoterate Meglumine API from the US Food and Drug Administration (hereinafter referred to as "FDA").
